A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma

International Journal of Radiation Oncology Biology Physics

Volumn 90, Issue 2, 2014, Pages 369-375

  Wuthrick, Evan J ^a   Curran, Walter J ^a   Camphausen, Kevin ^b   Lin, Alexander ^a   Glass, Jon ^a   Evans, James ^a   Andrews, David W ^a   Axelrod, Rita ^a   Shi, Wenyin ^a   Werner Wasik, Maria ^a   Haacke, E Mark ^c   Hillman, Gilda G ^c   Dicker, Adam P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL LIFE; MAGNETIC RESONANCE IMAGING; RADIOTHERAPY; TUMORS;

HIGH-GRADE GLIOMAS; INTRACEREBRAL HEMORRHAGES; LIFE EXPECTANCIES; METHODS AND MATERIALS; PROGRESSION FREE SURVIVAL; THERAPEUTIC RATIOS; VASCULAR NORMALIZATION; WORLD HEALTH ORGANIZATION;

TOXICITY;

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; SUNITINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; APHASIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN HEMORRHAGE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANDIDIASIS; CLINICAL ARTICLE; COUGHING; DIARRHEA; DOSIMETRY; ESOPHAGITIS; FATIGUE; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; HYPOCHLOREMIA; HYPOFRACTIONATED STEREOTACTIC RADIATION THERAPY; HYPONATREMIA; HYPOPROTEINEMIA; LEUKOPENIA; LIFE EXPECTANCY; MALE; MIDDLE AGED; MUSCLE WEAKNESS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PAIN; PILOT STUDY; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; XEROSTOMIA; BRAIN NEOPLASMS; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROCEDURES; RADIATION DOSE FRACTIONATION; RADIOSURGERY; REMISSION; RETREATMENT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOMA; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; PYRROLES; RADIOSURGERY; REMISSION INDUCTION; RETREATMENT;

EID: 84908249084     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.05.034     Document Type: Article

References (34)

1. T.J. Abrams, L.B. Lee, and L.J. Murray SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer Mol Cancer Ther 2 2003 471 478
2. D.B. Mendel, A.D. Laird, and X. Xin In vivo antitumor activity of su11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 2003 327 337
3. L. Sun, C. Liang, and S. Shirazian Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3z)-ylidenemethyl]-2,4- dimethyl-1h-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase J Med Chem 46 2003 1116 1119
4. E. Raymond, L. Dahan, and J.L. Raoul Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 2011 501 513
5. S. de Bouard, P. Herlin, and J.G. Christensen Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma Neuro Oncol 9 2007 412 423
6. L. Geng, E. Donnelly, and G. McMahon Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy Cancer Res 61 2001 2413 2419
7. D.H. Gorski, M.A. Beckett, and N.T. Jaskowiak Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation Cancer Res 59 1999 3374 3378
8. S.V. Kozin, Y. Boucher, and D.J. Hicklin Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts Cancer Res 61 2001 39 44
9. K.C. Cuneo, L. Geng, and A. Fu Su11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation Int J Radiat Oncol Biol Phys 71 2008 873 879
10. P. Wachsberger, R. Burd, and A.P. Dicker Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction Clin Cancer Res 9 2003 1957 1971
11. R.K. Jain Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy Science 307 2005 58 62
12. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy Nat Med 7 2001 987 989
13. P. Wachsberger, R. Burd, and A.P. Dicker Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways Hematol Oncol Clin North Am 18 2004 1039 1057 viii
14. C.G. Lee, M. Heijn, and E. di Tomaso Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions Cancer Res 60 2000 5565 5570
15. M.W. Dewhirst, Y. Cao, and B. Moeller Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response Nat Rev Cancer 8 2008 425 437
16. E.T. Shinohara, C. Cao, and K. Niermann Enhanced radiation damage of tumor vasculature by mtor inhibitors Oncogene 24 2005 5414 5422
17. B. Li, E.E. Sharpe, and A.B. Maupin VEGF and PlGF promote adult vasculogenesis by enhancing epc recruitment and vessel formation at the site of tumor neovascularization FASEB J 20 2006 1495 1497
18. Y. Shaked, A. Ciarrocchi, and M. Franco Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors Science 313 2006 1785 1787
19. Y. Su, L. Zheng, and Q. Wang The PI3K/Akt pathway upregulates id1 and integrin alpha4 to enhance recruitment of human ovarian cancer endothelial progenitor cells BMC Cancer 10 2010 459
20. S.E. Fogh, D.W. Andrews, and J. Glass Hypofractionated stereotactic radiation therapy: An effective therapy for recurrent high-grade gliomas J Clin Oncol 28 2010 3048 3053
21. M.M. Oken, R.H. Creech, and D.C. Tormey Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
22. B. Escudier, J. Roigas, and S. Gillessen Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4068 4075
23. S. George, J.Y. Blay, and P.G. Casali Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure Eur J Cancer 45 2009 1959 1968
24. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf.
25. E.L.M.P. Kaplan Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457
26. P.G. Corn, D.Y. Song, and E. Heath Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: Results from a multi-institutional phase 1 study Int J Radiat Oncol Biol Phys 86 2013 540 545
27. J. Jakob, G. Rauch, and F. Wenz Phase I trial of concurrent sunitinib and radiation therapy as preoperative treatment for soft tissue sarcoma BMJ Open 3 2013 e003626
28. E.J. Wuthrick, M. Kamrava, and W.J. Curran Jr. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies Cancer 117 2011 5548 5559
29. J. Kao, C.T. Chen, and C.C. Tong Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: Final report of a prospective clinical trial Target Oncol 9 2014 145 153
30. H.S. Friedman, M.D. Prados, and P.Y. Wen Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
31. B. Neyns, J. Sadones, and C. Chaskis Phase II study of sunitinib malate in patients with recurrent high-grade glioma J Neurooncol 103 2011 491 501
32. D.A. Reardon, K.L. Fink, and T. Mikkelsen Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme J Clin Oncol 26 2008 5610 5617
33. S.E. Combs, C. Thilmann, L. Edler, J. Debus, and D. Schulz-Ertner Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution J Clin Oncol 23 2005 8863 8869
34. P.H. Gutin, F.M. Iwamoto, and K. Beal Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas Int J Radiat Oncol Biol Phys 75 2009 156 163